Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series
Experimental Dermatology · 2023
DOI: 10.1111/exd.14810 ↗Kurz gefasst
Leserbrief in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Chang-Yu Hsieh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Psoriasis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan.
ORCID-Profile: Chang-Yu Hsieh, Tsen-Fang Tsai
Zitieren
APA
Hsieh, C. Y., & Tsai, T. F. (2023). Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series. Experimental Dermatology. https://doi.org/10.1111/exd.14810
Vancouver
Hsieh CY, Tsai TF. Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series. Experimental Dermatology. 2023. doi:10.1111/exd.14810
BibTeX
@article{Hsieh2023,
author = {Hsieh, Chang-Yu and Tsai, Tsen-Fang},
title = {Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14810}
}
EUVIMED